Angion Biomedica Corp.

14.29-0.5200-3.51%Vol 59.22K1Y Perf -16.45%
Apr 13th, 2021 16:00 DELAYED
BID14.17 ASK14.29
Open14.81 Previous Close14.81
Pre-Market- After-Market-
 - -  - -%
Target Price
59.33 
Analyst Rating
— — 0.00
Potential %
315.19 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
     40.15
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
★★ —    48.03
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap421.33M 
Earnings Rating
Price Range Ratio 52W %
12.59 
Earnings Date
-

Today's Price Range

14.0514.81

52W Range

12.5626.30

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Neutral
Performance
1 Week
-10.80%
1 Month
-30.12%
3 Months
-
6 Months
-
1 Year
-16.45%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
ANGN14.29-0.5200-3.51
AAPL134.433.19002.43
GOOG2 267.2712.48000.55
MSFT258.312.40000.94
XOM55.710.21000.38
WFC39.79-0.9800-2.40
JNJ159.48-2.1600-1.34
FB309.76-1.7800-0.57
GE13.44-0.1500-1.10
JPM154.09-1.8600-1.19
Financial StrengthValueIndustryS&P 500US Markets
0.40
0.40
0.27
0.43
-
Leverage Ratio -0.50
ProfitabilityValueIndustryS&P 500US Markets
58.70
-1 784.30
-1 764.50
-1 192.00
-
RevenueValueIndustryS&P 500US Markets
2.88M
0.10
-39.09
-
Earnings HistoryEstimateReportedSurprise %
Q04 2020-1.30-1.90-46.15
----
----
----
----
----
----
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date-
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume59.22K
Shares Outstanding29.48M
Trades Count796
Dollar Volume3.14M
Avg. Volume188.65K
Avg. Weekly Volume68.92K
Avg. Monthly Volume156.30K
Avg. Quarterly Volume188.65K

Angion Biomedica Corp. (NASDAQ: ANGN) stock closed at 14.29 per share at the end of the most recent trading day (a -3.51% change compared to the prior day closing price) with a volume of 59.23K shares and market capitalization of 421.33M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 53 people. Angion Biomedica Corp. CEO is Jay Venkatesan.

The one-year performance of Angion Biomedica Corp. stock is -16.45%, while year-to-date (YTD) performance is %. ANGN stock has a five-year performance of %. Its 52-week range is between 12.56 and 26.3, which gives ANGN stock a 52-week price range ratio of 12.59%

Angion Biomedica Corp. currently has a PE ratio of -5.60, a price-to-book (PB) ratio of 43.84, a price-to-sale (PS) ratio of 151.62, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -270.48%, a ROC of -368.92% and a ROE of 146.94%. The company’s profit margin is -%, its EBITDA margin is -1 764.50%, and its revenue ttm is $2.88 Million , which makes it $0.10 revenue per share.

Of the last four earnings reports from Angion Biomedica Corp., there were 0 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Angion Biomedica Corp.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Angion Biomedica Corp. is (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for Angion Biomedica Corp. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Angion Biomedica Corp. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Angion Biomedica Corp. has a Neutral technical analysis rating based on Technical Indicators (ADX : 19.69, ATR14 : 1.50, CCI20 : -187.81, Chaikin Money Flow : -0.38, MACD : 0.29, Money Flow Index : 32.86, ROC : -20.61, RSI : 46.88, STOCH (14,3) : 4.97, STOCH RSI : 0.38, UO : 33.89, Williams %R : -95.03), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Angion Biomedica Corp. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
0
Moderate Buy
0
0
0
Hold
0
0
0
Moderate Sell
0
0
0
Strong Sell
0
0
0
Summary Rating---

Angion Biomedica Corp.

Angion Biomedica Corp was incorporated in the State of Delaware on April 6. 1998. It is a clinical stage biopharmaceutical company. The Company discovers and develops novel therapeutic agents to treat acute and chronic organ injury by harnessing the body's protective, reparative and regenerative systems. It is developing therapeutics for both orphan indications and large clinical markets of unmet medical need.

CEO: Jay Venkatesan

Telephone: +1 516 326-1200

Address: 51 Charles Lindbergh Boulevard, Uniondale 11553, NY, US

Number of employees: 53

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

60%40%

Bearish Bullish

75%25%

Bearish Bullish

60%40%

News

Stocktwits